Education
About Us
Working with TipRanks
Follow Us
Barinthus Biotherapeutics (BRNS)
NASDAQ:BRNS
BRNS Stock Chart & Stats
$0.76
>-$0.01(-0.43%)
At close: 4:00 PM EST
$0.76
>-$0.01(-0.43%)
Day’s Range― - ―
52-Week Range$0.64 - $2.92
Previous CloseN/A
Volume10.26K
Average Volume (3M)124.73K
Market Cap
$30.82M
Enterprise Value-$13.18M
Total Cash (Recent Filing)$74.27M
Total Debt (Recent Filing)$11.57M
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Mar 20, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding40,830,353
10 Day Avg. Volume97,530
30 Day Avg. Volume124,726
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.37
Price to Sales (P/S)3.18
P/FCF Ratio-1.60
Enterprise Value/Market Cap-0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.19
Forecast
1Y Price Target
$4.00Price Target Upside426.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical SafetyPositive safety and tolerability signals from the single ascending dose portion of the first‑in‑human VTP‑1000 trial, with no treatment‑related serious adverse events and evidence of immune recognition without serious inflammation, support continued development in celiac disease.
Diabetes Program DevelopmentCLY‑101 has shown safety and supportive PK/PD in healthy volunteers and the Phase two a trial in Type 2 diabetes is underway with topline results expected in the second half of 2026, potentially validating its use for Type 1 and Type 2 diabetes.
Strategic TransactionDefinitive all‑stock merger agreement with Clywedog Therapeutics, expected to close in the first half of 2026, should create a combined company with three assets targeting metabolic and autoimmune diseases and strengthen the overall pipeline.
Bears Say
Barinthus Biotherapeutics News
BRNS FAQ
What was Barinthus Biotherapeutics’s price range in the past 12 months?
Barinthus Biotherapeutics lowest stock price was $0.64 and its highest was $2.92 in the past 12 months.
What is Barinthus Biotherapeutics’s market cap?
Barinthus Biotherapeutics’s market cap is $30.82M.
When is Barinthus Biotherapeutics’s upcoming earnings report date?
Barinthus Biotherapeutics’s upcoming earnings report date is Mar 20, 2026 which is in 63 days.
How were Barinthus Biotherapeutics’s earnings last quarter?
Barinthus Biotherapeutics released its earnings results on Nov 07, 2025. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.395 by $0.035.
Is Barinthus Biotherapeutics overvalued?
According to Wall Street analysts Barinthus Biotherapeutics’s price is currently Undervalued.
Does Barinthus Biotherapeutics pay dividends?
Barinthus Biotherapeutics does not currently pay dividends.
What is Barinthus Biotherapeutics’s EPS estimate?
Barinthus Biotherapeutics’s EPS estimate is -0.35.
How many shares outstanding does Barinthus Biotherapeutics have?
Barinthus Biotherapeutics has 40,830,353 shares outstanding.
What happened to Barinthus Biotherapeutics’s price movement after its last earnings report?
Barinthus Biotherapeutics reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.395. Following the earnings report the stock price went down -10.084%.
Which hedge fund is a major shareholder of Barinthus Biotherapeutics?
Currently, no hedge funds are holding shares in BRNS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Barinthus Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (426.32% Upside)
$4.00 (426.32% Upside)
Blogger Sentiment
Bullish
BRNS Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.13%
12-Months-Change
Fundamentals
Return on Equity
-62.30%
Trailing 12-Months
Asset Growth
-42.13%
Trailing 12-Months
Company Description
Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
BRNS Stock 12 Month Forecast
Average Price Target
$4.00
▲(426.32% Upside)
Technical Analysis
Collplant Holdings
―
ALX Oncology Holdings
―
Aligos Therapeutics
―
CytoMed Therapeutics Limited
―
Boundless Bio Inc.
―
Ownership Overview
3.49%
Insiders
0.03% Mutual Funds
21.79% Other Institutional Investors
74.69% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---